INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18601, 6080, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18602, 6575, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18603, 6577, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18604, 6819, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18605, 6821, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18606, 6824, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18607, 7625, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18608, 7628, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18609, 7633, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18610, 10352, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18611, 13189, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18612, 14739, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18613, 14888, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18614, 16781, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18615, 17266, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18616, 17267, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18617, 17268, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18618, 17269, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18619, 17270, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18620, 19333, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18621, 19539, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18622, 19556, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18623, 19871, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18624, 19872, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18625, 20442, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18626, 21299, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18627, 21301, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18628, 21303, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18629, 21305, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18630, 21982, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18631, 21983, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18632, 22139, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18633, 22143, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18634, 22145, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18635, 22146, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18636, 22147, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18637, 22148, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18638, 22150, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18639, 22154, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18640, 23147, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18641, 23148, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18642, 23429, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18643, 23431, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18644, 23432, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18645, 23434, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18646, 23446, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18647, 23447, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18648, 23448, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18649, 23736, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18650, 23737, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18651, 24038, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18652, 24455, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18653, 24456, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18654, 24457, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18655, 24458, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18656, 25156, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18657, 25157, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18658, 25158, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18659, 25159, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18660, 25160, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18661, 25161, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18662, 25162, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18663, 25163, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18664, 25164, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18665, 25165, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18666, 25166, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18667, 25167, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18668, 25168, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18669, 25169, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18670, 25170, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18671, 25171, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18672, 25172, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18673, 25173, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18674, 25184, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18675, 25185, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18676, 25531, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18677, 25532, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18678, 26350, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18679, 26832, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18680, 27113, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18681, 27114, 'Pregabalin', 'Cardiac Conduction System Disease', 'Pregabalin should be administered cautiously in patients with preexisting conduction abnormalities (e.g., marked first-degree AV block or second- or third-degree AV block), as it has been associated with PR interval prolongation.  In a clinical trial, the mean PR interval increase was 3 to 6 msec with pregabalin at doses higher than or equal to 300 mg per day.  This mean change difference was not associated with an increased risk of PR increase >=25% from baseline, an increased percentage of subjects with on-treatment PR >200 msec, or an increased risk of adverse reactions of second or third degree AV block.  Subgroup analyses did not identify an increased risk of PR prolongation in patients with baseline PR prolongation or in patients taking other PR prolonging medications.  However, these analyses cannot be considered definitive because of the limited number of patients in these categories.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18682, 31135, 'Procyclidine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18683, 31136, 'Procyclidine', 'Diabetic Neuropathies', 'Agents with anticholinergic activity can exacerbate many of the manifestations of autonomic neuropathy, including tachycardia, anhidrosis, bladder atony, obstipation, dry mouth and eyes, cycloplegia and blurring of vision, and sexual impotence in males.  Therapy with antimuscarinic agents and higher dosages of antispasmodic agents (e.g., dicyclomine or oxybutynin) should be administered cautiously in patients with autonomic neuropathy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18684, 31135, 'Procyclidine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18685, 31136, 'Procyclidine', 'Intestinal Obstruction', 'Anticholinergics are contraindicated in patients with obstructive diseases such as achalasia, esophageal stricture or stenosis, pyloroduodenal stenosis, stenosing peptic ulcer, pyloric obstruction, and paralytic ileus.  Anticholinergics may further suppress intestinal motility with resultant precipitation or aggravation of toxic megacolon.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18686, 31135, 'Procyclidine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18687, 31136, 'Procyclidine', 'Glaucoma', 'Anticholinergic agents are contraindicated in patients with primary glaucoma, a tendency toward glaucoma (narrow anterior chamber angle), or adhesions (synechiae) between the iris and lens, as well as for the elderly and others in whom undiagnosed glaucoma or excessive pressure in the eye may be present.  Because anticholinergics cause mydriasis, they may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18688, 31135, 'Procyclidine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18689, 31136, 'Procyclidine', 'Urinary Bladder Neck Obstruction', 'In general, the use of anticholinergic agents is contraindicated in patients with urinary retention and bladder neck obstruction caused by prostatic hypertrophy.  Dysuria may occur and may require catheterization.  Also, anticholinergic drugs may aggravate partial obstructive uropathy.  Caution is advised even when using agents with mild to moderate anticholinergic activity, particularly in elderly patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18690, 31135, 'Procyclidine', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18691, 31136, 'Procyclidine', 'Tardive Dyskinesia', 'Anticholinergic agents and agents with secondary anticholinergic activity may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Therapy with these agents should be avoided, if possible, or administered cautiously in patients with preexisting tardive dyskinesia, particularly in the elderly.  If tardive dyskinesia symptoms develop or worsen during treatment with an anticholinergic agent, prompt withdrawal of therapy will provide better chances of improving the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18692, 31135, 'Procyclidine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18693, 31136, 'Procyclidine', 'Dysentery', 'The use of drugs with antiperistaltic activity (primarily antidiarrheal and antimuscarinic agents, but also antispasmodic agents such as dicyclomine or oxybutynin at high dosages) is contraindicated in patients with diarrhea due to pseudomembranous enterocolitis or enterotoxin-producing bacteria.  These drugs may prolong and/or worsen diarrhea associated with organisms that invade the intestinal mucosa, such as toxigenic E. coli, Salmonella and Shigella, and pseudomembranous colitis due to broad-spectrum antibiotics.  Other symptoms and complications such as fever, shedding of organisms and extraintestinal illness may also be increased or prolonged.  In general, because antiperistaltic agents decrease gastrointestinal motility, they may delay the excretion of infective gastroenteric organisms or toxins and should be used cautiously in patients with any infectious diarrhea, particularly if accompanied by high fever or pus or blood in the stool.  Some cough and cold and other combination products may occasionally include antimuscarinic agents for their drying effects and may, therefore, require careful selection when necessary.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18694, 31135, 'Procyclidine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18695, 31136, 'Procyclidine', 'Heart Diseases', 'Anticholinergics block vagal inhibition of the SA nodal pacemaker.  Therapy with anticholinergics should be administered cautiously to patients with tachycardia, congestive heart failure, or coronary artery disease.  Premature ventricular depolarization, ventricular tachycardia, and fibrillation associated with anticholinergics are rare.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18696, 31135, 'Procyclidine', 'Liver Diseases', 'The clearance of anticholinergics may be decreased in the presence of liver disease.  Therapy with anticholinergics should be administered cautiously and may require less frequent dosing to avoid adverse effects in patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18697, 31136, 'Procyclidine', 'Liver Diseases', 'The clearance of anticholinergics may be decreased in the presence of liver disease.  Therapy with anticholinergics should be administered cautiously and may require less frequent dosing to avoid adverse effects in patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18698, 31135, 'Procyclidine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18699, 31136, 'Procyclidine', 'Hypertension', 'Cardiovascular effects of anticholinergics may exacerbate hypertension.  Therapy with anticholinergic agents should be administered cautiously in patients with hypertension.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18700, 31135, 'Procyclidine', 'Hyperthyroidism', 'In general, agents with anticholinergic activity may exacerbate hyperthyroidism.  Therapy with anticholinergics should be administered cautiously in patients with hyperthyroidism.  Thyroid levels should be monitored if usage is prolonged.', '1', '', 'DDInter', 0);
